Accepting Cases

Dexilant

Dexilant, generic name dexlansoprazole, belongs to a class of powerful acid-suppressing medicines called proton pump inhibitors (PPIs). These drugs may cause rare, life-threatening side effects. Dexilant is one of several PPIs named in lawsuits over serious kidney problems.

Dexilant (dexlansoprazole), like other proton pump inhibitors (PPIs), suppresses the body’s ability to produce stomach acid.

A modified version of lansoprazole (Prevacid), Dexilant delivers time-released doses in two waves. The first is released within an hour of taking the drug. The second release happens about four to five hours later.

Dexilant is available by prescription only in 30- and 60-milligram doses. There is no generic version or over-the-counter version of the drug. People with liver disease should not exceed a daily 30-mg dosage of Dexilant.

Takeda Pharmaceuticals manufactures Dexilant. The U.S. Food and Drug Administration approved Dexilant for use in adults in January 2009. In 2016, the FDA approved Dexilant to treat certain patients from 12 through 17 years old.

What Is Dexilant Used to Treat?

Dexilant is a heartburn medication approved to treat certain conditions caused by excessive stomach acid. Other PPIs, including Prilosec, Nexium, Prevacid and Protonix, may be approved for more uses than Dexilant.

FDA Approved Uses for Dexilant
  • Healing erosive esophagitis (EE)
  • Maintenance of healed EE
  • Relief of heartburn with healed EE
  • Treating gastroesophageal reflux disease (GERD)

Serious Dexilant Side Effects

Dexilant shares many of the same proton pump inhibitor side effects with other drugs in its class. The class of drugs has been on the market since the 1990s. In that time, countless studies have looked at the potential risks of taking PPIs long-term. In addition, PPI lawsuits blame the drugs for causing serious injuries to the people who took them.

Possible Dexilant Side Effects
  • Acute interstitial nephritis (AIN)
  • Artery damage
  • Bone fractures in children
  • Children’s heart defects
  • Heart attack
  • Esophageal cancer
  • Increased asthma and allergy risks for children
  • Hip, wrist and spine fractures
  • Infections
  • Kidney failure
  • Kidney injury
  • Stomach cancer
  • Stroke
  • Chronic kidney damage (CDK)

Stopping Dexilant Suddenly Can Cause Health Problems

People should never stop taking Dexilant suddenly. Doing so can cause symptoms to return at a greater intensity than before. It can also create new health problems.

People taking Dexilant or any other PPI should stop only after talking with their doctor and working out a plan to safely stop. In some cases, a doctor may be able to prescribe a proton pump inhibitor alternative. But in others, a doctor may determine that continuing Dexilant is a safer option than switching to another treatment.

Dexilant Warnings About Serious Side Effects

The Dexilant label carries several warnings and precautions about potentially serious side effects. But it does not list all potential Dexilant side effects. The FDA requires manufacturers add warnings to a drug label when there is increased scientific evidence of a possible risk.

Dexilant Label Warnings and Precautions
  • Acute interstitial nephritis (AIN) – a type of kidney injury
  • Bone fracture
  • Can interfere with diagnosing neuroendocrine tumors
  • Fundic gland polyps
  • Gastric malignancy
  • Clostridium difficile-associated diarrhea
  • Cutaneous and systemic lupus erythematosus
  • Interactions with cancer drug methotrexate
  • Magnesium deficiency
  • Vitamin B12 deficiency

Dexilant does not have a black box warning, the most serious warning the FDA can require.

People should talk with their doctor about other drugs they are taking before taking Dexilant. More than 1,800 drug products may cause proton pump inhibitor interactions if taken with Dexilant or other PPIs.

Common Dexilant Side Effects

Minor Dexilant side effects are more likely than serious side effects. Common Dexilant side effects for adults are slightly different from those adolescents may experience.

Common Dexilant Side Effects for Adults
  • Diarrhea
  • Abdominal pain
  • Nausea
  • Upper respiratory tract infection
  • Vomiting
  • Flatulence
Common Dexilant Side Effects for 12-Through-17-Year-Olds
  • Headache
  • Abdominal Pain
  • Diarrhea
  • Swelling of nasal passages & back of throat
  • Pain in the mouth and nose

Studies Associate Dexilant with Kidney Problems

Studies have associated long-term PPI use with serious kidney complications since the 1990s.

A 2017 study in the journal Kidney International found that PPIs, such as Dexilant, were linked to gradual but silent kidney damage.

The study said that doctors often rely on patients showing signs of kidney problems before stopping PPI use. But researchers found that more than half the patients who developed kidney damage showed no sign until the damage was done.

Kidney Problems Associated with Dexilant and other PPIs
  • Kidney failure
  • Kidney disease
  • Kidney injury (acute interstitial nephritis)
Suffering kidney complications after taking Dexilant? Get a Free Case Review

Dexilant Acute Kidney Injury (AIN) Risk

Long-term use of Dexilant or other PPIs may increase the risk of a serious kidney injury called acute interstitial nephritis (AIN). AIN is defined by kidney inflammation. It can often be treated if caught early, but in rare cases it can cause permanent damage.

Left untreated, AIN can lead to metabolic acidosis. That’s a condition in which the kidneys cannot remove acid from the blood. It can cause kidney failure and end-stage kidney disease.

Symptoms of AIN Include
  • Blood in the urine
  • Fever
  • Nausea
  • Vomiting
  • Swelling of any part of the body
  • Water retention
  • Weight gain
  • Mental changes (drowsiness, confusion or coma)
  • Changes in urine output (either increased or decreased)

People who experience symptoms of AIN should contact their doctor immediately.

Dexilant and Kidney Disease

Studies have found that people who take PPIs may have a higher risk of serious kidney disease.

Infographic of Dexilant and kidney failure.

A 2016 study in JAMA Internal Medicine compared people who took heartburn drugs with those who didn’t. Researchers found that PPI users had a 20 to 50 percent higher risk of chronic kidney disease (CKD). But people who took H2 blockers, such as Pepcid or Zantac, had no similar risk.

Another 2016 study in the Journal of the American Society of Nephrology also found an association between PPIs, such as Dexilant, and kidney disease. It found that long-term PPI users were 95 percent more likely than people who didn’t take the drugs to experience kidney failure. The study also found that PPI users were 28 percent more likely to develop CKD.

Studies Associate Dexilant with Cancer and Heart Attack Risks

Other studies have shown long-term PPI use may increase the risk of other serious conditions, including cancers and heart attacks.

Diagram of esophageal cancer in a human.
PPIs may be responsible for many esophageal cancer cases.

A 2018 study published in Cancer Epidemiology found PPIs may be responsible for a surprising number of esophageal cancer cases. Researchers examined the medical records of 796,492 people in Sweden who took PPIs during a seven-year period. They concluded that long-term PPI use may have been responsible for one in every 20 esophageal cancer cases in the country.

A 2017 study in the journal Gut found that taking PPIs could more than double the risk of stomach cancer. That same year, the FDA added a gastric-malignancy warning to the labels of Dexilant and other PPIs. The warning advises people to consider screening for gastric cancer if their response to drug is below standard.

A 2015 study published in the journal PLOS One found that long-term PPI use was associated with an increased risk of heart attacks among the general population. Another study in PLOS One found an association between PPI use and fatal heart failure among people with coronary artery disease. The 2017 research found that the risk increased for people taking higher doses of PPIs.

Dexilant Lawsuits and Kidney Damage

People who suffered serious kidney problems after taking Dexilant have filed lawsuits over their injuries. Dexilant lawsuits are among thousands filed against manufacturers of several different brands of PPIs. The lawsuits have been combined in a multidistrict litigation (MDL) in a New Jersey federal court. MDLs allow several similar lawsuits to move more quickly through the legal process.

As of August 2018, there were 4,725 lawsuits pending in the proton pump inhibitor MDL.

People who filed PPI lawsuits claim Dexilant or other PPIs caused kidney disease, injury or other serious conditions.

Please seek the advice of a medical professional before making health care decisions.

Terry Turner
Written By Terry Turner Writer

Terry Turner has been writing articles and producing news broadcasts for more than 25 years. He covers FDA policy, proton pump inhibitors, and medical devices such as hernia mesh, IVC filters, and hip and knee implants. An Emmy-winning journalist, he has reported on health and medical policy issues before Congress, the FDA and other federal agencies. Some of his qualifications include:

  • American Medical Writers Association (AMWA) and The Alliance of Professional Health Advocates member
  • Centers for Disease Control and Prevention Health Literacy certificates
  • Original works published or cited in Washington Examiner, MedPage Today and The New York Times
  • Appeared as an expert panelist on hernia mesh lawsuits on the BBC
Edited By

25 Cited Research Articles

  1. American Heart Association. (2016, November 15). Popular Heartburn Medication May Increase Ischemic Stroke Risk. Retrieved from  https://www.eurekalert.org/pub_releases/2016-11/aha-phm110316.php
  2. Antoniou, T. (2015, April 2). Proton Pump Inhibitors and the Risk of Acute Kidney Injury in Older Patients: A Population-Based Cohort Study. Retrieved from  https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4571830/
  3. Bhandari, T. (2017, July 3). Popular Heartburn Drugs Linked to Higher Death Risk. Retrieved from  https://medicine.wustl.edu/news/popular-heartburn-drugs-linked-higher-death-risk/
  4. Brusselaers, N., Engstrand, L. and Lagergren, J. (2018, February 22). Maintenance Proton Pump Inhibition Therapy and Risk of Oesophageal Cancer. Retrieved from  https://www.sciencedirect.com/science/article/pii/S1877782118300687?via%3Dihub
  5. Cheung, K.S. et al. (2017, December 2017). Long-Term Proton Pump Inhibitors and Risk of Gastric Cancer Development After Treatment for Helicobacter pylori: A Population-Based Study. Retrieved from  http://gut.bmj.com/content/67/1/28
  6. Cheung, K.S. et al. (2017, September 18). Long-term Proton Pump Inhibitors and Risk of Gastric Cancer Development After Treatment for Helicobacter pylori: A Population-based Study. Retrieved from  http://gut.bmj.com/content/early/2017/09/18/gutjnl-2017-314605
  7. Goldman, B. (2015, June 10). Some heartburn drugs may boost risk of heart attack, study finds. Retrieved from  https://med.stanford.edu/news/all-news/2015/06/some-heartburn-drugs-may-boost-risk-of-heart-attack-study-finds.html
  8. Healio Gastroenterology. (2016, July 13). FDA Approves Dexilant for Patients Aged 12 to 17 Years with GERD. Retrieved from https://www.healio.com/gastroenterology/motility/news/online/%7B7a76c97e-223a-4d42-8810-722c34c011e7%7D/fda-approves-dexilant-for-patients-aged-12-to-17-years-with-gerd
  9. Latif, W. (2017, August 1). Interstitial Nephritis. Retrieved from https://medlineplus.gov/ency/article/000464.htm
  10. Lazarus, B., et al. (2016, February 29). Proton Pump Inhibitor Use and the Risk of Chronic Kidney Disease. JAMA Internal Medicine. Retrieved from https://jamanetwork.com/journals/jamainternalmedicine/fullarticle/2481157
  11. Metz, D.C. et al. (2009, April 1). Review Article, Dual Delayed Release Formulation of Dexlansoprazole MR, a Novel Approach to Overcome the Limitations of Conventional Single Release Proton Pump Inhibitor Therapy. Alimentary Pharmacology and Therapeutics. Retrieved from https://onlinelibrary.wiley.com/doi/abs/10.1111/j.1365-2036.2009.03984.x
  12. Pello Lázaro, A.M. et al. (2017, January 9). Use of Proton-Pump Inhibitors Predicts Heart Failure and Death in Patients with Coronary Artery Disease. Retrieved from  http://journals.plos.org/plosone/article?id=10.1371/journal.pone.0169826
  13. Sauerwein, K. (2017). Popular heartburn drugs linked to gradual yet “silent” kidney damage. Retrieved from  https://medicine.wustl.edu/news/popular-heartburn-drugs-linked-gradual-yet-silent-kidney-damage/
  14. Shah, N. H. et al. (2015, June 10). Proton Pump Inhibitor Usage and the Risk of Myocardial Infarction in the General Population. Retrieved from  http://journals.plos.org/plosone/article?id=10.1371/journal.pone.0124653
  15. Stoppard, M. (2018, January 18). Taking Antacid Tablets on a Regular Basis Can Increase Your Risk of Cancer. The Mirror. Retrieved from  https://www.mirror.co.uk/lifestyle/health/taking-antacid-tablets-regular-basis-11874208
  16. Takeda Pharmaceuticals. (n.d.). Dexilant. Retrieved from https://www.dexilant.com/
  17. Takeda Pharmaceuticals. (2018, June). Medication Guide; Dexilant (decks-i-launt) (dexlansoprazole) Delayed-Release Capsules, for Oral Use. Retrieved from https://general.takedapharm.com/DEXILANTMG
  18. Tariq, R. et al. (2017, June). Association of Gastric Acid Suppression with Recurrent Clostridium difficile Infection. Retrieved from  http://jamanetwork.com/journals/jamainternalmedicine/article-abstract/2612117
  19. U.S. Food and Drug Administration. (2018, June 7). Drugs@FDA: FDA Approved Drug Products; New Drug Application (NDA): 022287. Retrieved from https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&varApplNo=022287
  20. U.S. Food and Drug Administration. (2012, February 8). FDA Drug Safety Communication: Clostridium difficile-associated diarrhea can be associated with stomach acid drugs known as proton pump inhibitors (PPIs). Retrieved from  https://www.fda.gov/drugs/drugsafety/ucm290510.htm
  21. U.S. Food and Drug Administration. (2018, June 7). Highlights of Prescribing Information (Dexilant label). Retrieved from https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/022287s029s030lbl.pdf
  22. Xie, Y. et al. (2017, June). Long-Term Kidney Outcomes among Users of Proton Pump Inhibitors without Intervening Acute Kidney Injury. Retrieved from  https://www.kidney-international.org/article/S0085-2538%2817%2930005-4/abstract
  23. Xie, Y. et al. (2017, June). Risk of death among users of Proton Pump Inhibitors: A longitudinal observational cohort study of United States Veterans. Retrieved from  http://bmjopen.bmj.com/content/7/6/e015735
  24. Xie, Y. et al. (2016, April 14). Proton Pump Inhibitors and Risk of Incident CKD and Progression to ESRD. Retrieved from  https://www.ncbi.nlm.nih.gov/pubmed/27080976
  25. U.S. Judicial Panel on Multidistrict Litigation. (2018, August 15). MDL Statistics Report. Retrieved from http://www.jpml.uscourts.gov/sites/jpml/files/Pending_MDL_Dockets_By_District-August-15-2018.pdf
View All Sources
Who Am I Calling?

Calling this number connects you with Wilson and Peterson, LLP or one of its trusted legal partners. A law firm representative will review your case for free.

Wilson and Peterson, LLP funds Drugwatch because it supports the organization’s mission to keep people safe from dangerous drugs and medical devices.

(844) 440-8662

To contact Drugwatch Managing Editor Kevin Connolly, call (855) 839-9780.